127 related articles for article (PubMed ID: 15542358)
1. Efficacy of different targeting agents in the photolysis of interleukin-2 receptor bearing cells.
Linares R; Pacheco JR; Good TA
J Photochem Photobiol B; 2004 Dec; 77(1-3):17-26. PubMed ID: 15542358
[TBL] [Abstract][Full Text] [Related]
2. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
Waldmann TA; Goldman CK
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
[TBL] [Abstract][Full Text] [Related]
3. Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera.
Sogo T; Kawahara M; Tsumoto K; Kumagai I; Ueda H; Nagamune T
J Immunol Methods; 2008 Aug; 337(1):16-23. PubMed ID: 18589435
[TBL] [Abstract][Full Text] [Related]
4. [Interleukin 2 (IL-2) and its receptor (IL-2R) in healthy individuals and with various disease states].
Mazur G; Frydecka I
Acta Haematol Pol; 1993; 24(4):307-13. PubMed ID: 8303976
[TBL] [Abstract][Full Text] [Related]
5. IL-2 receptor expression in the haematologic malignancies: a target for immunotherapy.
Waldmann TA
Cancer Surv; 1989; 8(4):891-903. PubMed ID: 2701734
[TBL] [Abstract][Full Text] [Related]
6. Requirement of high-affinity IL-2-IL-2R interaction for T cell anergy induction.
Hayashi RJ; Kanagawa O
Int Immunol; 2006 May; 18(5):645-51. PubMed ID: 16574670
[TBL] [Abstract][Full Text] [Related]
7. Soluble interleukin 2 receptors are released by long term-cultured insulin-specific T cells transiently after contact with antigen.
Reske-Kunz AB; Osawa H; Josimović-Alasević O; Rüde E; Diamantstein T
J Immunol; 1987 Jan; 138(1):192-6. PubMed ID: 3097145
[TBL] [Abstract][Full Text] [Related]
8. Early immune response and regulation of IL-2 receptor subunits.
Hughes-Fulford M; Sugano E; Schopper T; Li CF; Boonyaratanakornkit JB; Cogoli A
Cell Signal; 2005 Sep; 17(9):1111-24. PubMed ID: 15993752
[TBL] [Abstract][Full Text] [Related]
9. Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors.
Chu JW; Sharom FJ
Immunology; 1993 May; 79(1):10-7. PubMed ID: 8509130
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation by interleukin-2 receptor targeted therapy.
Gupta D; Naik S
Natl Med J India; 1994; 7(2):67-70. PubMed ID: 8019399
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
12. Identification of the interleukin-2 receptor (IL-2R) on human leukemic T cells using colloidal gold and scanning electron microscopy.
Helinski EH; Bielat KL; Ovak GM; Meenaghan MA; Wirth JE; Pauly JL
J Med; 1988; 19(5-6):353-68. PubMed ID: 3264564
[TBL] [Abstract][Full Text] [Related]
13. Clinical importance of interleukin-2 receptor alpha-chain expression in acute leukemia. The Japan Cooperative Group of Leukemia/Lymphoma.
Nakase K; Kita K; Kageyama S; Tsuji K; Miyanishi E; Miwa H; Tanaka I; Shirakawa S; Tanaka I; Anazawa H; Tsutani H; Kyo T; Dohy H; Kamada N; Doi S; Nasu K; Uchino H
Cancer Detect Prev; 1997; 21(3):273-9. PubMed ID: 9167045
[TBL] [Abstract][Full Text] [Related]
14. IL-2-PE40 is cytotoxic for activated T lymphocytes expressing IL-2 receptors.
Ogata M; Lorberboum-Galski H; FitzGerald D; Pastan I
J Immunol; 1988 Dec; 141(12):4224-8. PubMed ID: 3264309
[TBL] [Abstract][Full Text] [Related]
15. [The expression of CD25 in phytohemagglutinin- or interleukin-2-stimulated human peripheral blood lymphocytes].
Zenin VV; Aksenov ND; Shatrova AN; Marakhova II
Tsitologiia; 2009; 51(6):506-10. PubMed ID: 19637754
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.
Volk HD; Josimovic-Alasevic O; Gross M; Diamantstein T
Clin Exp Immunol; 1989 Apr; 76(1):121-5. PubMed ID: 2786777
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive and anticancer effect of a mammalian ribonuclease that targets high-affinity interleukin-2-receptors.
Yamamura T; Ueda M; Psarras K; Suwa T; Watanaabe Y; Kameyama N; Tanabe M; Imamura H; Kitajima M
Eur J Surg; 2002; 168(1):49-54. PubMed ID: 12022372
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms.
Rasmusson I; Ringdén O; Sundberg B; Le Blanc K
Exp Cell Res; 2005 Apr; 305(1):33-41. PubMed ID: 15777785
[TBL] [Abstract][Full Text] [Related]
19. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections.
Bachmann MF; Wolint P; Walton S; Schwarz K; Oxenius A
Eur J Immunol; 2007 Jun; 37(6):1502-12. PubMed ID: 17492805
[TBL] [Abstract][Full Text] [Related]
20. Tumour-bearing animals synthesize a decreased level of mRNA for the inducible 55,000 MW interleukin-2 receptor.
Holán V; Lipoldová M
Immunology; 1990 Apr; 69(4):626-8. PubMed ID: 2335381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
